Flu Vaccine Market Outlook 2024: United States Opportunity and Demand Analysis, Market Forecast 2017-2024
Date: Apr-2016 | Id: MACRC-0059 | Geographical Scope: United States | Publisher: DPI Research
United States flu vaccine market is expected to reach nearly US$ 3 Billion by 2024. Growth in US flu vaccine market can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against flu vaccine and introduction of quadrivalent flu vaccine. Long–term Growth Projection and Development: • Sanofi to Acquire Protein Sciences Corporation • It is likely that more than 185 Million persons being vaccinated with flu vaccines in 2024. • Nearly 160 Million doses of flu vaccines have shipped to US for the 2017-2018 flu season • It is projected that GSK flu vaccine sales value will reach around US$ 1.5 Billion by 2024 • BiondVax reports positive phase 2b clinical trial results for its universal flu vaccine “Flu Vaccine Market Outlook 2024: United States Opportunity and Demand Analysis, Market Forecast 2017-2024” provides a deep and thorough evaluation of the United States flu vaccine market. The report provides an in–depth analysis of the flu vaccination pattern in both Children and Adults in the United States. It also provides essential insights into flu vaccine production, price, consumption, supply, distribution, demand and specification. It also covers reimbursement pattern and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials and promising flu vaccines in the clinical development. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players in the US flu vaccine market such as Sanofi Pasteur, GSK and Seqirus. The major market players are evaluated on various parameters such as company overview, product outlook, latest development & trends and sales analysis of flu vaccine market from 2011 to 2022. The report also entails major drivers and inhibitors in the US flu vaccine market. Key Topics Covered in the Report • Market Overview: United States Flu Vaccine Market (2010 - 2024) • United States Number of Persons Vaccinated with Flu Vaccine (2010 - 2024) • United States Flu Vaccine Production, Price, Consumption, Supply, Distribution, Demand and Specification • Reimbursement & Regulatory System in the US Flu Vaccine Market • Mergers, Acquisitions, Key Agreements & Collaborations • Promising Flu Vaccine in Clinical Development • Flu Vaccine Clinical Trial Insights by Phase, Company & Country • Key Drivers and Inhibitors of the US Flu Vaccine Market • Key Companies Analysis Major Flu Vaccines Covered Under This Report Are: • Fluzone High–Dose • Fluzone Quadrivalent • Intradermal (ID) Trivalent • Vaxigrip • Fluarix Quadrivalent • Flulaval Quadrivalent • Flucelvax Quadrivalent • Afluria Quadrivalent • Agrippal • Fluad • Fluvirin • Fluvax Key Companies Covered in This Report: • Seqirus • Sanofi Pasteur • GlaxoSmithKline(GSK)
1. Executive Summary 2. Market Overview: United States Flu Vaccine Market (2010 - 2024) 3. United States Number of Persons Vaccinated with Flu Vaccine (2010 - 2024) 3.1 Number of Children Vaccinated 3.2 Number of Adults Vaccinated 4. Key Drivers and Inhibitors of the United States Flu Vaccine Market 4.1 Market Drivers 4.2 Market Inhibitors 5. United States Flu Vaccine Production, Price, Consumption, Supply, Distribution, Demand and Specification 5.1 Flu Vaccine Price Trends 5.1.1 Pediatric Flu Vaccine Price Trends 5.1.2 Adult Flu Vaccine Price Trends 5.2 United States Flu Vaccine Production, Supply, and Allocation (By Companies) 5.3 United States Flu Vaccine Distribution & Demand 5.4 Flu Vaccine Effectiveness 5.5 Managing Flu with Rapid Diagnostic Testing 5.6 Distribution Method of Flu Vaccination 6. United States Flu Vaccine Market – Reimbursement & Regulatory System 6.1 Reimbursement System 6.2 Regulation System 7. Market Dynamics – Mergers, Acquisitions, Key Agreements & Collaborations 7.1 Merger & Acquisitions 7.2 Collaboration Deal 7.3 Licensing, Exclusive & Distribution Agreement Deal 7.3.1 Licensing Agreement 7.3.2 Exclusive Agreement 7.3.3 Distribution Agreement 8. Flu Vaccine – Promising Vaccine in Clinical Development 8.1 Quadrivalent Seasonal Influenza VLP Vaccine 8.2 VN – 100 8.3 Seasonal Influenza VLP Vaccine 8.4 M–001 9. Flu Vaccine – Clinical Trial Insights by Phase, Company & Country 9.1 Year 2017 9.2 Year 2016 10. Key Companies Analysis 10.1 Sanofi Pasteur 10.1.1 Business Overview 10.1.2 Flu Vaccine Outlook 10.1.2.1 Fluzone High–Dose Vaccine 10.1.2.2 Fluzone Quadrivalent Vaccine 10.1.2.3 Intradermal (ID) Trivalent Flu Vaccine 10.1.2.4 Vaxigrip Vaccine 10.1.3 Flu Vaccine Sales Analysis & Forecast (2011 - 2024) 10.1.4 Flu Vaccine – Latest Development and Trends 10.2 GlaxoSmithKline (GSK) 10.2.1 Business Overview 10.2.2 Flu Vaccine Outlook 10.2.2.1 Fluarix Quadrivalent 10.2.2.2 Flulaval Quadrivalent 10.2.3 Flu Vaccine Sales Analysis & Forecast (2011 - 2024) 10.2.4 Flu Vaccine – Latest Development & Trends 10.3 Seqirus (CSL Limited) 10.3.1 Business Overview 10.3.2 Flu Vaccine Outlook 10.3.2.1 Flucelvax Quadrivalent 10.3.2.2 Afluria Quadrivalent 10.3.2.3 Agrippal 10.3.2.4 Fluad 10.3.2.5 Fluvirin 10.3.2.6 Fluvax 10.3.3 Flu Vaccine – Latest Development & Trends
Related reports
United States Influenza Vaccine Market
$1000-$1400
United States Blood Glucose Test Strips Market
$1290-$1990